LEVETIRACETAM IN TREATMENT OF EPILEPSY, OWN EXPERIENCE OF APPLICATION IN ADULT PATIENTS

• Main Author: G. G. Toropina
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2017-05-01
• Series: Медицинский совет
• Subjects: levetiracetam; idiopathic generalized epilepsy; juvenile myoclonic epilepsy; idiopathic focal epilepsy; symptomatic epilepsy; adult patients; efficacy; adverse effects
• Online Access: https://www.med-sovet.pro/jour/article/view/1868

Basic properties of Levetiracetam (LEV) were described and own experience of its application at the dose of 500–4000 mg/day in 95 patients at the age of 17–69 years (mean age 34 ± 13 years) with various epileptic syndromes was analyzed. The overall effect of LEV made 69.1%, remission at least a year was achieved in 43.6%, in 17% – for 3 years or more. The best result was observed in juvenile myoclonic epilepsy an improvement in 83.3% of patients, remission on LEV monotherapy in 75% of patients. High efficiency was also noted in idiopathic and symptomatic generalized epilepsy – an improvement making up 78.6 and 81.3%, respectively. Idiopathic focal epilepsy LEO showed less efficiency – about 51.5%. Adverse effects were observed in 12 patients (12,8%), of which only in 3 the LEV was replaced because of the development of apathy, fatigue and the appearance of efficiency violations as a result of aggravate focal seizures. In other cases drowsiness, irritability and increased unprovoked aggression were observed, these side effects passed within the first month of treatment. The obtained results confirm the high efficacy and good tolerability of LEV.